Retatrutide vs Tirzepatide vs CagriSema

Research-use format note: Keep evidence comparison separate from format selection. For in-vitro retatrutide format checks, compare the 10mg research pen, 20mg research pen (99.841% HPLC), 30mg flagship pen, 40mg research pen, 10mg vial, and 40mg vial. Tirzepatide research-use material is covered separately on the Tirzepatide 40mg vial page; trust proof and lab-volume routes live in verified researcher reviews and wholesale RFQ.

How This Comparison Was Checked

This page separates four evidence types: peer-reviewed anchor trials, official company Phase 3 disclosures, FDA approval materials, and ClinicalTrials.gov records. The core sources behind this update are the New England Journal of Medicine retatrutide phase 2 paper, the SURMOUNT-1 tirzepatide paper, Lilly’s TRIUMPH-1, TRIUMPH-4, and TRANSCEND-T2D-1 releases, Novo Nordisk’s REDEFINE 4 and CagriSema NDA announcements, the May 2026 CagriSema device-pivot reporting, the June 2026 semaglutide-versus-tirzepatide model-based dose-response analysis, and current trial registry records.

Cross-trial comparisons are useful, but they are not the same as a randomized head-to-head. That matters here because tirzepatide has direct comparator data against CagriSema, while retatrutide does not yet have a published direct comparison against either of the other two compounds. This page is for research interpretation only and does not double as a product-detail page.

Weight Loss: Which Signal Leads?

For pure weight loss ceiling, retatrutide currently leads the three-way comparison. Lilly’s 2023 phase 2 paper reported up to 24.2% mean body-weight reduction at 48 weeks. The pivotal TRIUMPH-1 Phase 3 obesity readout (May 21, 2026) reported 28.3% at 80 weeks on 12 mg in adults with obesity and no T2D, rising to 30.3% at 104 weeks in the BMI ≥35 extension. Dose-by-dose: 4 mg 19.0%, 9 mg 25.9%, 12 mg 28.3%, with 45.3% of 12 mg participants achieving ≥30% weight loss. TRIUMPH-4 separately reported 28.7% at 68 weeks in adults with obesity or overweight and knee osteoarthritis. That is the strongest published signal among these three compounds, but it is still an investigational result — Lilly has not filed an NDA, and the full TRIUMPH-1 data set will be presented at the ADA Scientific Sessions in June 2026.

Tirzepatide remains the approved benchmark. In SURMOUNT-1, the 15 mg dose produced 20.9% mean weight loss at 72 weeks, which helped establish tirzepatide as the reference point for modern weight loss medications. If the question is which option in this set has the strongest approved incretin-based performance for weight management, tirzepatide is the answer because it combines large obesity datasets, FDA approval, and broad real-world use.

CagriSema remains highly relevant because Novo Nordisk’s fixed dose combination still posted major results. REDEFINE 1 reported 22.7% mean body weight reduction at 68 weeks if all participants adhered to treatment. But the February 23, 2026 REDEFINE 4 readout put the combination under real pressure: the treatment regimen estimand showed 20.2% for CagriSema versus 23.6% for tirzepatide at 84 weeks, while the if-all-participants-adhered analysis showed 23.0% versus 25.5%. CagriSema failed non-inferiority in this ~809-participant open-label obesity trial. The follow-on news in May 2026 was a device pivot: Novo will launch with a dual-pen device rather than the originally planned single-chamber co-formulation. The Novo CEO has framed the launch plan as unchanged on substance, but the device switch is the most visible operational signal since the NDA filing on December 18, 2025. That is why CagriSema stays in the conversation, but tirzepatide still sets the direct benchmark and retatrutide still owns the highest investigational weight loss potential.

Blood Sugar and Glycemic Control

Beyond weight loss, blood sugar control is one of the clearest reasons tirzepatide still matters in a three-way comparison. Tirzepatide is already approved for type 2 diabetes as Mounjaro, and the SURPASS program gives it the deepest evidence base for HbA1c lowering, fasting glucose improvement, and long-term metabolic follow-up. As a dual GLP-1 and GIP agonist, it improves insulin release in a glucose-dependent way while also reducing appetite and lowering overall energy intake.

Retatrutide adds a third receptor arm to that story. Lilly’s March 19, 2026 TRANSCEND-T2D-1 release reported mean HbA1c reductions of 1.7% to 2.0% across doses at 40 weeks, with participants taking retatrutide 12 mg also losing 16.8% of baseline body weight. That matters because retatrutide does not just work through GLP-1 and GIP biology; the glucagon receptor arm changes metabolism, energy expenditure, and substrate use in ways that keep it central to late-stage clinical research in obesity and type 2 diabetes.

CagriSema combines semaglutide with a long acting amylin analogue, so its glucose story is different again. Novo Nordisk’s 2025 annual reporting described REDEFINE 2 results showing 15.7% mean weight reduction in adults with type 2 diabetes and obesity or overweight if all participants adhered to treatment. The rationale is that cagrilintide adds satiety and post-meal control signals on top of semaglutide’s known blood sugar effects. In short: tirzepatide has the deepest approved diabetes base, retatrutide has the most expansive next-generation metabolic medicine signal, and CagriSema remains the most advanced amylin-plus-GLP-1 combination.

Mechanism: Triple Agonist vs Dual Agonist vs Fixed Dose Combination

Retatrutide works by activating three receptors in one molecule: GLP-1, GIP, and glucagon. That is why it is repeatedly described as a triple agonist. The GLP-1 and GIP arms support appetite control, blood sugar regulation, and incretin biology, while the glucagon arm appears to increase energy expenditure and help the body burn more calories. Mechanistically, retatrutide is the broadest tool in this comparison.

Tirzepatide is simpler in structure but still powerful. It is a single peptide that activates GLP-1 and GIP, making it the classic dual-incretin benchmark. It does not have retatrutide’s glucagon arm, so its weight loss story is driven more by appetite suppression, reduced food intake, and improved glycemic signaling than by a direct energy-expenditure effect. That is one reason tirzepatide stays central to the field: it translates strong weight loss with a cleaner mechanism and a much larger approved evidence base.

CagriSema is different again because it is not one molecule at all. It is a fixed dose combination of semaglutide plus cagrilintide. Novo’s thesis is that cagrilintide adds non-overlapping amylin biology to semaglutide’s GLP-1 effects. In practical terms, that means CagriSema combines appetite and satiety signals rather than broadening receptor count. This is why the three-way comparison matters: retatrutide tests maximal receptor breadth, tirzepatide tests a validated dual-incretin model, and CagriSema tests whether an amylin-plus-GLP-1 combination can remain relevant against both.

Clinical Trials and Ongoing Research

All three compounds sit at very different stages of clinical research. Retatrutide is still investigational, but the program is broad. Lilly has already reported positive Phase 3 data in TRIUMPH-4 for obesity plus knee osteoarthritis and in TRANSCEND-T2D-1 for type 2 diabetes. ClinicalTrials.gov also shows a large TRIUMPH program spanning obesity, sleep apnea, cardiovascular outcomes, kidney outcomes, and comparator studies. Lilly still describes retatrutide as legally available only to participants in Lilly clinical trials.

Tirzepatide has the deepest finished record by far. The SURMOUNT program established its obesity efficacy, the SURPASS program established its diabetes performance, and FDA approvals have already followed. In the U.S., tirzepatide is approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. FDA also approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity on December 20, 2024. For a practical walkthrough of tirzepatide dosing and studies, see our Mounjaro (tirzepatide) guide.

CagriSema is the middle case: later stage than retatrutide, but not yet approved like tirzepatide. Novo Nordisk submitted the U.S. NDA on December 18, 2025 based on REDEFINE 1 and REDEFINE 2, and later said an FDA decision is anticipated by late 2026. REDEFINE 4 already gave it direct comparator data against tirzepatide, while REDEFINE 11 and a higher-dose CagriSema trial are intended to test whether the current package still has more weight loss upside. For milestone tracking across all three, use the obesity drug approval tracker.

Dosing Comparison

All three are studied or used as once-weekly subcutaneous injections, but the dosing logic is not identical. Retatrutide studies typically titrate from low weekly doses toward 12 mg. Tirzepatide’s approved regimen starts at 2.5 mg and escalates toward 15 mg. CagriSema is not a dose ladder of two separate products in practice; it is a fixed dose combination studied at set semaglutide/cagrilintide ratios, most prominently 2.4 mg/2.4 mg once weekly.

That difference matters when reading outcomes. Tirzepatide and retatrutide are single molecules with multi-receptor activity built into one peptide. CagriSema instead asks whether a pre-set amylin-plus-GLP-1 pairing can outperform the best single-molecule incretin drugs. For retatrutide-specific titration math and device framing, use our retatrutide dosage guide.

Side Effects and Safety Profile

The safety overlap is real: all three compounds mainly live inside a familiar incretin-style tolerability pattern, with gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation leading the conversation. For detailed frequency context, see our Ozempic vs Mounjaro vs Wegovy side effects comparison and the retatrutide side effects guide. Across retatrutide, tirzepatide, and CagriSema, the most common adverse events still cluster around escalation and usually ease over time.

Tirzepatide still has the strongest safety base because it has moved beyond trials and into approved use. That does not make it side-effect free, but it does mean researchers can lean on a broader labeling package, larger exposure base, and longer follow-up. Retatrutide’s record now extends into Phase 3: the TRIUMPH-1 readout reported a clear dose-dependent discontinuation-due-to-AE curve of 4.1% / 6.9% / 11.3% across 4 / 9 / 12 mg vs 4.9% placebo, and new Phase 3 AEs included dysesthesia up to 12.5% on 12 mg alongside UTIs. That confirms the dysesthesia signal flagged in Phase 2 and gives prescribers and competitors a real curve to argue about ahead of the full ADA presentation in June 2026.

CagriSema did not win the head-to-head on efficacy, but Novo Nordisk described REDEFINE 4 as showing a safe and well-tolerated profile, with gastrointestinal events that were largely mild to moderate and diminished over time. So the main safety question is not whether CagriSema sits outside the incretin class pattern; it is whether the added amylin biology can keep enough of its existing benefits to remain competitive against stronger or more established options.

The clean read for researchers is straightforward: tirzepatide has the lowest uncertainty because it is approved, retatrutide has the biggest upside but more unresolved long-term questions, and CagriSema stays in the middle as a late-stage combination with a class-familiar profile but a less decisive efficacy story.

Regulatory and Market Availability in 2026

As of June 8, 2026, tirzepatide is the only one of these three compounds with full FDA approval. Mounjaro was approved on May 13, 2022 for type 2 diabetes, and Zepbound followed on November 8, 2023 for chronic weight management. FDA later expanded Zepbound in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity. That makes tirzepatide the only true marketed benchmark in this set.

CagriSema is closer to market than retatrutide but is still not approved. Novo Nordisk submitted the U.S. NDA on December 18, 2025; an FDA decision is expected late 2026 with no public PDUFA date. In May 2026, Novo confirmed a device pivot: the commercial product will use a dual-pen format rather than the originally planned single-chamber co-formulation. So if the question is which investigational asset is closest to launch, the answer is CagriSema, not retatrutide — though the device switch is a real operational signal.

Retatrutide is still investigational and Lilly has not filed an NDA as of June 8, 2026. TRIUMPH-2 (T2D) and TRIUMPH-3 (established CVD) readouts are expected later in 2026, and the full TRIUMPH-1 obesity data will be presented at the ADA Scientific Sessions in June 2026. On this site, UAE-specific routing for research-use formats lives on Retatrutide UAE, but that should not be confused with therapeutic approval, prescription availability, or FDA approval.

If someone asks, “Is there anything better than retatrutide?” the answer depends on what they value. For approved access, labeling depth, and current market presence, tirzepatide wins. For raw investigational weight loss ceiling, retatrutide still leads. For the Novo Nordisk route built around amylin plus GLP-1 biology, CagriSema remains relevant but did not beat tirzepatide in direct data.